News
Zacks Small Cap Research on MSN1mon
REVB Starts 2025 With Bright Future AheadThe company’s current therapeutic candidates are all based on the active ingredient PHAD, which is a synthetic version of MPLA, that is known to stimulate TLR-4. PHAD stimulation of TLR-4 leads ...
Hosted on MSN26d
REVB Announces Positive Test ResultsThe company’s current therapeutic candidates are all based on the active ingredient PHAD, which is a synthetic version of MPLA, that is known to stimulate TLR-4. PHAD stimulation of TLR-4 leads ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback